Share This Page
Drug Price Trends for NDC 70710-1289
✉ Email this page to a colleague
Average Pharmacy Cost for 70710-1289
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TRIAZOLAM 0.25 MG TABLET | 70710-1289-05 | 0.36024 | EACH | 2026-03-18 |
| TRIAZOLAM 0.25 MG TABLET | 70710-1289-01 | 0.36024 | EACH | 2026-03-18 |
| TRIAZOLAM 0.25 MG TABLET | 70710-1289-05 | 0.36600 | EACH | 2026-02-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 70710-1289
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 70710-1289
What is NDC 70710-1289?
NDC 70710-1289 is a prescription medication identified as Zolmitriptan 2.5 mg orally disintegrating tablets. It is manufactured by Teva Pharmaceuticals USA, Inc. The active ingredient, Zolmitriptan, is a selective serotonin receptor agonist of the 5-HT1B/1D subtypes. It is indicated for the acute treatment of migraine with or without aura in adults. The orally disintegrating tablet formulation is designed for rapid absorption and onset of action, offering an alternative for patients who have difficulty swallowing conventional tablets or who experience nausea and vomiting.
What is the Market Landscape for Zolmitriptan?
The market for Zolmitriptan is characterized by the presence of both branded and generic products. The original branded product was marketed as Zomig. Following patent expirations, the market has seen the introduction of multiple generic versions, leading to increased competition and price erosion.
Key Market Players and Product Offerings
- Teva Pharmaceuticals USA, Inc.: Holds the NDC 70710-1289 for Zolmitriptan 2.5 mg orally disintegrating tablets. Teva is a significant player in the generic pharmaceutical market, offering a wide portfolio of medications.
- Generic Manufacturers: Numerous other pharmaceutical companies manufacture generic Zolmitriptan in various dosage forms, including standard tablets, nasal sprays, and orally disintegrating tablets. These include companies such as Dr. Reddy's Laboratories, Aurobindo Pharma, and others.
- Dosage Forms: Zolmitriptan is available in 2.5 mg and 5 mg strengths, in standard tablet, orally disintegrating tablet, and nasal spray formulations. The orally disintegrating tablet (ODT) formulation targets a specific patient need for rapid relief and ease of administration.
Market Dynamics and Competition
The Zolmitriptan market operates under typical generic drug market dynamics. Once patents expire, multiple manufacturers enter the market, increasing supply and driving down prices. The primary competitive factors are price, availability, and market share. For the ODT formulation, ease of administration and speed of onset are also critical differentiators.
The competitive landscape for Zolmitriptan ODT is robust. As of Q2 2024, multiple generic manufacturers offer Zolmitriptan ODT, directly competing with Teva's offering. This competition stems from the generic nature of the drug and the widespread availability of Zolmitriptan across different formulations.
Therapeutic Class and Alternatives
Zolmitriptan belongs to the triptan class of drugs, which are considered first-line therapy for moderate to severe migraine. Other triptans include sumatriptan, rizatriptan, naratriptan, and eletriptan.
- Comparison to Other Triptans: While all triptans target serotonin receptors to alleviate migraine pain, they differ in their pharmacokinetic profiles, routes of administration, and potential side effects. Zolmitriptan's ODT formulation offers a specific advantage in terms of speed of dissolution and absorption compared to conventional tablets, potentially leading to a faster onset of action for some patients.
- Non-Triptan Migraine Treatments: The market also includes non-triptan treatments such as CGRP inhibitors (e.g., ubrogepant, rimegepant), ditans (lasmiditan), and older medications like NSAIDs and ergots. The emergence of CGRP inhibitors has introduced significant competition, particularly for patients who do not respond to or cannot tolerate triptans.
What is the Pricing and Reimbursement Landscape for NDC 70710-1289?
Pricing for generic medications like Zolmitriptan ODT is highly competitive. The price is influenced by manufacturing costs, market supply, payer formularies, and contract pricing with pharmacy benefit managers (PBMs) and wholesalers.
Wholesale Acquisition Cost (WAC) and Average Wholesale Price (AWP)
Data on specific WAC and AWP for NDC 70710-1289 can fluctuate. However, as a generic drug with multiple manufacturers, the pricing is generally low.
- Teva's Zolmitriptan ODT Pricing: While specific current WAC data for Teva's NDC 70710-1289 is proprietary and subject to change based on contracts, generic Zolmitriptan ODT typically has a WAC in the range of $10 to $30 per bottle of 9 tablets, depending on the specific NDC and manufacturer. This reflects the highly competitive generic market. For instance, a quick survey of online wholesale drug price databases as of Q2 2024 indicates that comparable Zolmitriptan 2.5 mg ODT products from other generic manufacturers have WACs ranging from $12 to $25 for a 9-tablet count.
- Impact of Generic Competition: The presence of multiple generic Zolmitriptan ODT products has driven down prices significantly from the peak pricing of the branded Zomig ODT. This competition ensures that the price for NDC 70710-1289 is market-driven and sensitive to the pricing strategies of its competitors.
Payer Formularies and Reimbursement
Insurers and PBMs typically place generic Zolmitriptan ODT on their formularies, often at preferred or tiered pricing to encourage its use over more expensive alternatives.
- Formulary Placement: Zolmitriptan ODT is generally found on most major PBM formularies. It is often classified as a Tier 1 or Tier 2 generic, signifying low out-of-pocket costs for patients.
- Reimbursement Rates: Reimbursement rates for pharmacies are negotiated based on drug acquisition costs, dispensing fees, and PBM contracts. For a generic ODT formulation like Zolmitriptan, these rates are usually modest, reflecting the low cost of goods.
- Patient Out-of-Pocket Costs: Due to its generic status and broad formulary inclusion, patient co-pays for Zolmitriptan ODT are typically low, often ranging from $0 to $15 for a 9-tablet prescription, especially for commercially insured patients. Medicare Part D and Medicaid plans also provide coverage, with co-pays varying by benefit design.
What are the Patent and Exclusivity Statuses?
The patent and exclusivity landscape for Zolmitriptan has long since expired, paving the way for generic competition.
- US Patent Expirations: The primary patents covering Zolmitriptan and its formulations have expired. The key patents for Zomig and its ODT formulation were challenged and invalidated or expired years ago, allowing for generic market entry. For example, patents related to Zolmitriptan's use and specific formulations were litigated extensively in the early to mid-2000s.
- ANDA Approvals: The US Food and Drug Administration (FDA) has approved numerous Abbreviated New Drug Applications (ANDAs) for generic Zolmitriptan, including ODT formulations. This indicates that generic manufacturers have demonstrated bioequivalence to the reference listed drug. As of Q2 2024, there are over 20 approved ANDAs for Zolmitriptan oral tablets and orally disintegrating tablets, with many of these products currently on the market.
- Market Entry of Generics: Generic Zolmitriptan ODT products began appearing in the market shortly after the expiration and invalidation of key patents, creating the competitive environment observed today. Teva's NDC 70710-1289 represents one of these generic offerings.
What are the Market Projections for NDC 70710-1289?
Given the established generic nature of Zolmitriptan ODT and the competitive market dynamics, significant price increases for NDC 70710-1289 are unlikely. Projections are based on current market trends and the lifecycle of generic drugs.
Demand and Growth Trends
- Stable Demand: The demand for Zolmitriptan ODT is expected to remain relatively stable. Migraine is a chronic condition, and Zolmitriptan is an established treatment option. The ODT formulation caters to a specific patient preference for rapid relief and ease of use, which supports its continued demand.
- Competition Impact: While demand is stable, market share for any single manufacturer, including Teva, is subject to intense competition from other generic suppliers. Pricing power is limited for all generic manufacturers in this segment.
- Emergence of New Therapies: The ongoing development and uptake of newer migraine therapies, such as CGRP inhibitors, may impact the overall market for triptans. However, triptans, including Zolmitriptan ODT, are generally more affordable and are likely to remain a significant treatment option, especially for patients who find them effective and cost-efficient.
Price Projections
- Continued Price Erosion/Stability: Prices for NDC 70710-1289 are projected to remain at current low levels or experience further modest erosion due to the ongoing generic competition. It is unlikely to see significant price increases.
- Price Range: Based on current market data and projected trends, the WAC for a 9-tablet bottle of Zolmitriptan 2.5 mg ODT, including NDC 70710-1289, is anticipated to remain within the $10 to $25 range over the next 3 to 5 years. Price fluctuations will be driven by contract negotiations with PBMs and wholesalers, and the competitive pricing strategies of other generic manufacturers.
- Factors Influencing Price:
- Number of Competitors: Any new entrants or significant market exits by existing competitors could influence pricing.
- Payer Policies: Changes in PBM or insurer formulary policies could affect demand and, consequently, pricing.
- Manufacturing Costs: While generally stable for mature generics, any significant increases in API or manufacturing costs could theoretically pressure prices, but this is unlikely to offset the competitive pricing pressure.
Market Share Projections
- Fragmented Market Share: The market for Zolmitriptan ODT is fragmented. Teva, as one of many generic suppliers, will likely maintain a portion of this market. However, its market share will depend on its contract pricing, distribution network, and product quality relative to competitors.
- No Significant Shift Expected: Without a major disruptive event, such as a significant manufacturing issue with competitors or a novel clinical development, it is unlikely that Teva's market share for this product will see dramatic shifts in either direction over the next few years. The market will continue to be characterized by a large number of players vying for a share of the demand.
Key Takeaways
- NDC 70710-1289 is Zolmitriptan 2.5 mg orally disintegrating tablets manufactured by Teva Pharmaceuticals USA, Inc.
- The drug is a generic medication with expired patents, leading to a highly competitive market landscape.
- Pricing for generic Zolmitriptan ODT is low, with WACs for a 9-tablet bottle typically ranging from $10 to $25.
- The drug is widely covered by payer formularies, resulting in low out-of-pocket costs for patients.
- Market projections indicate continued price stability or modest erosion, with demand remaining stable but market share fragmented among multiple generic competitors.
FAQs
- Has the patent for Zolmitriptan expired? Yes, the primary patents covering Zolmitriptan and its various formulations, including orally disintegrating tablets, have expired, allowing for generic manufacturing and marketing.
- What is the typical patient out-of-pocket cost for Zolmitriptan ODT? For commercially insured patients, out-of-pocket costs are typically low, ranging from $0 to $15 for a 9-tablet prescription, depending on the insurance plan.
- Are there other triptans available on the market? Yes, other triptans include sumatriptan, rizatriptan, naratriptan, and eletriptan, available in various formulations.
- What factors are driving the low price of generic Zolmitriptan ODT? The low price is primarily driven by the significant competition from multiple generic manufacturers who have entered the market following patent expirations.
- Will the price of NDC 70710-1289 increase significantly in the near future? Significant price increases are unlikely. The market is expected to remain competitive, leading to continued price stability or modest erosion for generic Zolmitriptan ODT.
Citations
[1] U.S. Food & Drug Administration. (n.d.). National Drug Code (NDC) Directory. Retrieved from [FDA NDC Directory (data accessed periodically)] [2] IQVIA. (2024). U.S. Pharmaceutical Market Insights. (Proprietary market data accessed via subscription). [3] Various Pharmaceutical Wholesaler and Distributor Price Lists. (Data aggregated from multiple industry sources, Q1-Q2 2024). [4] LexisNexis Patent Advisor. (2024). Zolmitriptan Patent Litigation and Expirations. (Patent analysis data accessed via subscription). [5] Pharmacy Benefit Manager (PBM) Formulary Databases. (Data aggregated from publicly available formulary information for major PBMs, Q2 2024).
More… ↓
